Schering Receives Expanded Approval for MS Drug
RedNova Tue, 24 Oct 2006 1:08 PM PDT
Berlex, a US affiliate of Schering AG, has said that the FDA has expanded the indication of Betaseron to include patients with multiple sclerosis who have experienced their first clinical episode.

Link discovered between common cold viruses and Alzheimer's disease
News-Medical-Net Tue, 24 Oct 2006 12:13 PM PDT
According to new research memory loss and Alzheimer's disease may be linked to the very viruses which cause the common cold.

---

Tysabri

Analog Devices cuts 4th quarter revenue forecast
Boston Globe - United States
... (AP). Elan Corp. said its Tysabri treatment for multiple sclerosis was effective in treating Crohn's disease. About 86 percent of ...

Elan's Q3 losses worse than expected
RTE.ie - Ireland
The quarter saw the redistribution of its multiple sclerosis drug Tysabri for the first time since it was withdrawn in February 2005. ...
See all stories on this topic

Market report: Wed latest
This is Money - UK
... UBS is forecasting a net loss of $61.7m for Elan but the key focus will be on the likely uptake for its key Tysabri drug in the US and Europe. ...

Morning business news
RTE.ie - Ireland
SOLID START FOR TYSABRI SALES - Pharmaceuticals company Elan has this morning issued its third quarter figures to the end of September which show the company's ...

Elan Reports Third Quarter 2006 Financial Results
Genetic Engineering News (press release) - New Rochelle,NY,USA
... We are encouraged by the initial results in the relaunch of Tysabri for MS in the US market and the launch in the European markets. ...

Elan Q3 Loss Widens, Revenues Decline On Maxipime Supply Shortages ...
Trading Markets - Los Angeles,CA,USA
... The company is encouraged by the initial results from the relaunch of its Tysabri drug for multiple scleroris and sees a significant growth in Tysabri revenues ...
See all stories on this topic

Elan falls on Tysabri fears
Unison.ie - Bray,Ireland
... drugmaker Elan finished down 20c at the €12.10 level in Dublin yesterday as US doctors are proving wary about the company's multiple sclerosis drug, Tysabri. ...

Elan says 75% of Tysabri patients switched from other drugs
MarketWatch - USA
PLC (ELN) Wednesday said around 75% of patients now taking its multiple sclerosis drug Tysabri in both the US and EU have switched from other drug treatments. ...
See all stories on this topic